{"denoms":[{"counts":[{"groupId":"BG000","value":"18"}],"units":"Participants"}],"groups":[{"description":"Participants received 3 cycles of oral solution of Xevinapant at a dose of 200 milligrams per day (mg/day) once daily from Day 1 to 14, per 3-week cycle. The first three cycles are given in combination with Cisplatin at dose of 40 milligrams per square meter (mg/m2) once daily on Cycle 1 Day 2 (C1D2, C1D9, C1D16, C2D2, C2D9, C2D16, and C3D2) With 70 Gray (Gy) of intensity modulated radiation therapy (IMRT) in 35 fractions, 2 Gy/fraction, 5 days/week followed by 3 cycles of monotherapy of Xevinapant at a dose of 200 mg/day from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).","id":"BG000","title":"Sequence 1"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.19","value":"60"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"15"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Ethnicity-Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"Ethnicity-Not Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"Race-Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Race-Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Race-White"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}]}